Follow last change Jan 2020 re-read 9 days ago

THU

Developed for: sickle cell disease
Investigated by: EpiDestiny, Inc. · National Heart, Lung, and Blood Institute (NHLBI) · National Institutes of Health (NIH)

today NCT04055818 · Ph 1

2020202120222023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT04055818	Jan 2020 → Oct 2028 expected	sickle cell disease	EpiDestiny, Inc.	Recruiting	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	THU	“Oral 250 mg THU and 5 mg decitabine Once per week” NCT04055818 ↗
Route	Oral	“Oral 250 mg THU and 5 mg decitabine Once per week” NCT04055818 ↗